Compare UG & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | FGEN |
|---|---|---|
| Founded | 1942 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | UG | FGEN |
|---|---|---|
| Price | $6.03 | $8.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | 14.6K | ★ 26.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 11.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.43 | ★ 53.38 |
| Revenue | ★ $10,060,322.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.14 | ★ $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.58 | $4.85 |
| 52 Week High | $11.98 | $21.94 |
| Indicator | UG | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 38.23 |
| Support Level | $5.87 | $7.99 |
| Resistance Level | $6.10 | $9.09 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 87.49 | 34.82 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.